Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Lisa Bero, PhD

    TitleProfessor
    SchoolUCSF School of Pharmacy
    DepartmentClinical Pharmacy
    Address3333 Calif. St,Laurel Heights
    San Francisco CA 94143
    Phone415-476-1067

       Biography 
       Awards and Honors
      UCSF, Academic Senate2009Distinction in Mentoring Award
      Philip R. Lee Institute for Health Policy Studies, UCSF2009Harold Luft Award for Mentoring in Health Services and Health Policy Research
      McMaster University1998LaBelle Lectureship

       Overview 
       Overview
      Lisa A. Bero, PhD, Professor, Department of Clinical Pharmacy, School of Pharmacy and Institute for Health Policy Studies, School of Medicine, University of California, San Francisco, is a pharmacologist with primary interests in how clinical and basic sciences are translated into clinical practice and health policy. She has developed and validated methods for assessing bias in the design, conduct and dissemination of research on pharmaceuticals, tobacco and chemicals. Dr. Bero has also conducted analyses to examine the dissemination and policy implications of research evidence. Her international activities include advisor to the World Health Organization Department of Essential Medicines and Pharmaceutical Policies, member and chair of the WHO Essential Medicines Committee and member of the Pan American Health Organization Advisory Committee on Health Research. She is Director of the San Francisco Branch of the United States Cochrane Center and the World Health Organization Collaborating Centre on Pharmaceutical Research and Science Policy. She was an elected member of the Cochrane Collaboration Steering Group for 12 years and was appointed Co-Chair in 2013. Dr. Bero serves on several national and international committees related to conflicts of interest and research, such as the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education and Practice.


       ORNG Applications 
       Featured Publications
       Websites
       Featured Videos
       In The News
       Awarded Grants
       Global Health
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Tovey D, Churchill R, Bero L. Evidence based medicine: looking forward and building on what we have learnt. BMJ. 2014; 349:g4508.
        View in: PubMed
      2. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014; 4:MR000034.
        View in: PubMed
      3. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria: krauth et Al. Respond. Environ Health Perspect. 2014 Mar 1; 122(3):A67.
        View in: PubMed
      4. Coralic Z, Kanzaria HK, Bero L, Stein J. Staff Perceptions of an On-site Clinical Pharmacist Program in an Academic Emergency Department after One Year. West J Emerg Med. 2014 Mar; 15(2):205-10.
        View in: PubMed
      5. Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol. 2014 Jan; 12(1):e1001770.
        View in: PubMed
      6. Alexander PE, Bero L, Montori VM, Brito JP, Stoltzfus R, Djulbegovic B, Neumann I, Rave S, Guyatt G. World Health Organization recommendations are often strong based on low confidence in effect estimates. J Clin Epidemiol. 2014 Jun; 67(6):629-34.
        View in: PubMed
      7. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item. Cochrane Database Syst Rev. 2013; 12:ED000075.
        View in: PubMed
      8. Neltner TG, Alger HM, O'Reilly JT, Krimsky S, Bero LA, Maffini MV. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. JAMA Intern Med. 2013 Dec 9; 173(22):2032-6.
        View in: PubMed
      9. Chahal HS, St Fort N, Bero L. Availability, prices and affordability of essential medicines in Haiti. J Glob Health. 2013 Dec; 3(2):20405.
        View in: PubMed
      10. Grundy Q, Bero L, Malone R. Interactions between Non-Physician Clinicians and Industry: A Systematic Review. PLoS Med. 2013 Nov; 10(11):e1001561.
        View in: PubMed
      11. Apollonio DE, Glantz SA, Bero LA. Term limits and the tobacco industry. Soc Sci Med. 2014 Mar; 104:1-5.
        View in: PubMed
      12. Moynihan RN, Cooke GP, Doust JA, Bero L, Hill S, Glasziou PP. Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med. 2013 Aug; 10(8):e1001500.
        View in: PubMed
      13. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect. 2013 Sep; 121(9):985-92.
        View in: PubMed
      14. Wolfe N, Gøtzsche PC, Bero L. Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev. 2013; 2:31.
        View in: PubMed
      15. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ. 2013; 346:f2231.
        View in: PubMed
      16. Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013 Apr 8; 173(7):580-1.
        View in: PubMed
      17. Nguyen NY, Bero L. Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med. 2013 Mar 11; 173(5):338-43.
        View in: PubMed
      18. Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013; 2:CD010398.
        View in: PubMed
      19. Conway J, Bero L, Ondari C, Wasan KM. Review of the quality of pediatric medications in developing countries. J Pharm Sci. 2013 May; 102(5):1419-33.
        View in: PubMed
      20. Odierna DH, Forsyth SR, White J, Bero LA. The cycle of bias in health research: a framework and toolbox for critical appraisal training. Account Res. 2013; 20(2):127-41.
        View in: PubMed
      21. Taba P, Rosenthal M, Habicht J, Tarien H, Mathiesen M, Hill S, Bero L. Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res. 2012; 12:455.
        View in: PubMed
      22. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012; 12:MR000033.
        View in: PubMed
      23. Bero L, Busuttil G, Farquhar C, Koehlmoos TP, Moher D, Nylenna M, Smith R, Tovey D. Measuring the performance of the Cochrane library. Cochrane Database Syst Rev. 2012; 12:ED000048.
        View in: PubMed
      24. Bero LA, Hill S, Habicht J, Mathiesen M, Starkopf J. The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines. J Clin Epidemiol. 2013 Feb; 66(2):132-9.
        View in: PubMed
      25. Bero LA, Binder L. The Cochrane Collaboration review prioritization projects show that a variety of approaches successfully identify high-priority topics. J Clin Epidemiol. 2013 May; 66(5):472-3.
        View in: PubMed
      26. Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ. 2012; 345:e5155.
        View in: PubMed
      27. Anson A, Ramay B, de Esparza AR, Bero L. Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health. 2012; 8:22.
        View in: PubMed
      28. Hill S, Yang A, Bero L. Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One. 2012; 7(5):e38055.
        View in: PubMed
      29. Norris SL, Burda BU, Holmer HK, Ogden LA, Fu R, Bero L, Schünemann H, Deyo R. Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. J Clin Epidemiol. 2012 Jul; 65(7):725-33.
        View in: PubMed
      30. Malone RE, Grundy Q, Bero LA. Tobacco industry denormalisation as a tobacco control intervention: a review. Tob Control. 2012 Mar; 21(2):162-70.
        View in: PubMed
      31. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012; 344:d7202.
        View in: PubMed
      32. Sutton P, Woodruff TJ, Vogel S, Bero LA. Conrad and Becker's "10 Criteria" fall short of addressing conflicts of interest in chemical safety studies. Environ Health Perspect. 2011 Dec; 119(12):A506-7; author reply A508-9.
        View in: PubMed
      33. Walleser S, Hill SR, Bero LA. Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement. J Clin Epidemiol. 2011 Dec; 64(12):1331-40.
        View in: PubMed
      34. Krleža-Jeriç K, Lemmens T, Reveiz L, Cuervo LG, Bero LA. Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Rev Panam Salud Publica. 2011 Jul; 30(1):87-96.
        View in: PubMed
      35. Millar TP, Wong S, Odierna DH, Bero LA. Applying the essential medicines concept to US preferred drug lists. Am J Public Health. 2011 Aug; 101(8):1444-8.
        View in: PubMed
      36. Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA. 2011 Mar 9; 305(10):1008-17.
        View in: PubMed
      37. Dhruva SS, Bero LA, Redberg RF. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices. Circ Cardiovasc Qual Outcomes. 2011 Mar; 4(2):165-71.
        View in: PubMed
      38. Bero L, Ghersi D. Making systematic reviews global. Cochrane Database Syst Rev. 2011; (8):ED000020.
        View in: PubMed
      39. Smith R, Tovey D, Bero L, Busuttil G, Farquhar C, Koehlmoos TP, Moher D, Nylenna M, Pais P. The Cochrane Library Oversight Committee. Cochrane Database Syst Rev. 2011; (8):ED000021.
        View in: PubMed
      40. Ridge AL, Bero LA, Hill SR. Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia. BMC Health Serv Res. 2010; 10:340.
        View in: PubMed
      41. Chen CE, Dhruva SS, Bero LA, Redberg RF. Inclusion of training patients in US Food and Drug Administration premarket approval cardiovascular device studies. Arch Intern Med. 2011 Mar 28; 171(6):534-9.
        View in: PubMed
      42. Bero L, Carson B, Moller H, Hill S. To give is better than to receive: compliance with WHO guidelines for drug donations during 2000-2008. Bull World Health Organ. 2010 Dec 1; 88(12):922-9.
        View in: PubMed
      43. Cataldo JK, Bero LA, Malone RE. "A delicate diplomatic situation": tobacco industry efforts to gain control of the Framingham Study. J Clin Epidemiol. 2010 Aug; 63(8):841-53.
        View in: PubMed
      44. Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L. CONSORT 2010. Lancet. 2010 Jul 24; 376(9737):229-30.
        View in: PubMed
      45. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, Bero L. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010; (7):CD000336.
        View in: PubMed
      46. Robertson J, Walkom E, Moynihan R, Bero L, Henry D. Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. Int J Pharm Pract. 2010 Apr; 18(2):88-92.
        View in: PubMed
      47. Montini T, George A, Martin-Mollard M, Bero LA. The role of public participation in public health initiatives: an analysis of the WHO Framework Convention on Tobacco Control. Glob Public Health. 2010; 5(1):48-61.
        View in: PubMed
      48. Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009 Dec 23; 302(24):2679-85.
        View in: PubMed
      49. Rasmussen N, Lee K, Bero L. Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials. 2009; 10:116.
        View in: PubMed
      50. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009 Nov 12; 361(20):1963-71.
        View in: PubMed
      51. Robertson J, Moynihan R, Walkom E, Bero L, Henry D. Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med. 2009 Nov; 6(11):e1000128.
        View in: PubMed
      52. Cook DM, Bero LA. The politics of smoking in federal buildings: an executive order case study. Am J Public Health. 2009 Sep; 99(9):1588-95.
        View in: PubMed
      53. Apollonio DE, Bero LA. Evidence and argument in policymaking: development of workplace smoking legislation. BMC Public Health. 2009; 9:189.
        View in: PubMed
      54. Rattinger G, Bero L. Factors associated with results and conclusions of trials of thiazolidinediones. PLoS One. 2009; 4(6):e5826.
        View in: PubMed
      55. Odierna DH, Bero LA. Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations. J Clin Epidemiol. 2009 Dec; 62(12):1268-78.
        View in: PubMed
      56. Nkansah N, Nguyen T, Iraninezhad H, Bero L. Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes. Public Health Nutr. 2009 Oct; 12(10):1931-7.
        View in: PubMed
      57. Kummerfeldt CE, Barnoya J, Bero L. Philip Morris involvement in the development of an air quality laboratory in El Salvador. Tob Control. 2009 Jun; 18(3):241-4.
        View in: PubMed
      58. Cook DM, Gurugubelli RK, Bero LA. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings. Drug Saf. 2009; 32(11):1057-66.
        View in: PubMed
      59. White J, Bandura A, Bero LA. Moral disengagement in the corporate world. Account Res. 2009 Jan-Mar; 16(1):41-74.
        View in: PubMed
      60. Montini T, Bero LA. Implementation of a workplace smoking ban in bars: the limits of local discretion. BMC Public Health. 2008; 8:402.
        View in: PubMed
      61. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008 Nov 25; 5(11):e217; discussion e217.
        View in: PubMed
      62. Bero L. "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterprise. J Clin Epidemiol. 2008 Jul; 61(7):629-33.
        View in: PubMed
      63. Jewell CJ, Bero LA. "Developing good taste in evidence": facilitators of and hindrances to evidence-informed health policymaking in state government. Milbank Q. 2008 Jun; 86(2):177-208.
        View in: PubMed
      64. Finley PR, Bero L. Clarification of study and citation. Arch Intern Med. 2007 Dec 10; 167(22):2531; author reply 2531-2.
        View in: PubMed
      65. Cook DM, Boyd EA, Grossmann C, Bero LA. Reporting science and conflicts of interest in the lay press. PLoS One. 2007; 2(12):e1266.
        View in: PubMed
      66. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ. 2007 Dec 8; 335(7631):1202-5.
        View in: PubMed
      67. Boyd EA, Bero LA. Defining financial conflicts and managing research relationships: an analysis of university conflict of interest committee decisions. Sci Eng Ethics. 2007 Dec; 13(4):415-35.
        View in: PubMed
      68. Prochaska JJ, Hall SM, Bero LA. Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? Schizophr Bull. 2008 May; 34(3):555-67.
        View in: PubMed
      69. White J, Parascandola M, Bero L. Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds. Nicotine Tob Res. 2007 Nov; 9(11):1213-25.
        View in: PubMed
      70. Apollonio DE, Lopipero P, Bero LA. Participation and argument in legislative debate on statewide smoking restrictions. Health Res Policy Syst. 2007; 5:12.
        View in: PubMed
      71. Schick SF, Bero LA, Cook DM. The tobacco industry and the Data Quality Act. Science. 2007 Aug 17; 317(5840):898.
        View in: PubMed
      72. Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. WITHDRAWN: Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 1997; (2):CD000172.
        View in: PubMed
      73. Bero L. [Shall we ban industrial funds for research?]. Epidemiol Prev. 2007 Jul-Aug; 31(4):171-4.
        View in: PubMed
      74. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007 Jun; 4(6):e184.
        View in: PubMed
      75. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007 Apr; 4(4):e134.
        View in: PubMed
      76. Apollonio DE, Bero LA. The creation of industry front groups: the tobacco industry and "get government off our back". Am J Public Health. 2007 Mar; 97(3):419-27.
        View in: PubMed
      77. Dickersin K, Straus SE, Bero LA. Evidence based medicine: increasing, not dictating, choice. BMJ. 2007 Jan 6; 334 Suppl 1:s10.
        View in: PubMed
      78. Boyd EA, Bero LA. Improving the use of research evidence in guideline development: 4. Managing conflicts of interests. Health Res Policy Syst. 2006; 4:16.
        View in: PubMed
      79. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006 Aug 15; 145(4):284-93.
        View in: PubMed
      80. Hong MK, Bero LA. Tobacco industry sponsorship of a book and conflict of interest. Addiction. 2006 Aug; 101(8):1202-11.
        View in: PubMed
      81. Lopipero P, Bero LA. Tobacco interests or the public interest: 20 years of industry strategies to undermine airline smoking restrictions. Tob Control. 2006 Aug; 15(4):323-32.
        View in: PubMed
      82. Nguyen NT, Cook DM, Bero LA. The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the-counter status: a comparative case study. Clin Ther. 2006 Aug; 28(8):1231-43.
        View in: PubMed
      83. Lee KP, Boyd EA, Holroyd-Leduc JM, Bacchetti P, Bero LA. Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Med J Aust. 2006 Jun 19; 184(12):621-6.
        View in: PubMed
      84. Cook DM, Bero LA. Identifying carcinogens: the tobacco industry and regulatory politics in the United States. Int J Health Serv. 2006; 36(4):747-66.
        View in: PubMed
      85. Glaser BE, Bero LA. Attitudes of academic and clinical researchers toward financial ties in research: a systematic review. Sci Eng Ethics. 2005 Oct; 11(4):553-73.
        View in: PubMed
      86. Cook DM, Tong EK, Glantz SA, Bero LA. The power of paperwork: how Philip Morris neutralized the medical code for secondhand smoke. Health Aff (Millwood). 2005 Jul-Aug; 24(4):994-1004.
        View in: PubMed
      87. Bero LA, Glantz S, Hong MK. The limits of competing interest disclosures. Tob Control. 2005 Apr; 14(2):118-26.
        View in: PubMed
      88. Bero LA. Tobacco industry manipulation of research. Public Health Rep. 2005 Mar-Apr; 120(2):200-8.
        View in: PubMed
      89. Bero LA. Managing financial conflicts of interest in research. J Am Coll Dent. 2005; 72(2):4-9.
        View in: PubMed
      90. Baba A, Cook DM, McGarity TO, Bero LA. Legislating "sound science": the role of the tobacco industry. Am J Public Health. 2005; 95 Suppl 1:S20-7.
        View in: PubMed
      91. Dunsby J, Bero L. A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes. Tob Control. 2004 Dec; 13(4):362-9.
        View in: PubMed
      92. Lipton S, Boyd EA, Bero LA. Conflicts of interest in academic research: policies, processes, and attitudes. Account Res. 2004 Apr-Jun; 11(2):83-102.
        View in: PubMed
      93. Boyd EA, Lipton S, Bero LA. Implementation of financial disclosure policies to manage conflicts of interest. Health Aff (Millwood). 2004 Mar-Apr; 23(2):206-14.
        View in: PubMed
      94. White J, Bero LA. Public health under attack: the American Stop Smoking Intervention Study (ASSIST) and the tobacco industry. Am J Public Health. 2004 Feb; 94(2):240-50.
        View in: PubMed
      95. Michel MC, Bero LA, Bright T. Creating a text data-mining application for use in public health informatics. Conf Proc IEEE Eng Med Biol Soc. 2004; 5:3214-6.
        View in: PubMed
      96. Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA, Lee JY, Bero LA. Impact of a collaborative care model on depression in a primary care setting: a randomized controlled trial. Pharmacotherapy. 2003 Sep; 23(9):1175-85.
        View in: PubMed
      97. Malone RE, Bero LA. Chasing the dollar: why scientists should decline tobacco industry funding. J Epidemiol Community Health. 2003 Aug; 57(8):546-8.
        View in: PubMed
      98. Grimshaw J, McAuley LM, Bero LA, Grilli R, Oxman AD, Ramsay C, Vale L, Zwarenstein M. Systematic reviews of the effectiveness of quality improvement strategies and programmes. Qual Saf Health Care. 2003 Aug; 12(4):298-303.
        View in: PubMed
      99. Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med. 2003 Aug; 78(8):769-74.
        View in: PubMed
      100. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May 31; 326(7400):1167-70.
        View in: PubMed
      101. Bryan-Jones K, Bero LA. Tobacco industry efforts to defeat the occupational safety and health administration indoor air quality rule. Am J Public Health. 2003 Apr; 93(4):585-92.
        View in: PubMed
      102. Roth AL, Dunsby J, Bero LA. Framing processes in public commentary on US federal tobacco control regulation. Soc Stud Sci. 2003 Feb; 33(1):7-44.
        View in: PubMed
      103. Hong MK, Bero LA. How the tobacco industry responded to an influential study of the health effects of secondhand smoke. BMJ. 2002 Dec 14; 325(7377):1413-6.
        View in: PubMed
      104. Beney J, Devine EB, Chow V, Ignoffo RJ, Mitsunaga L, Shahkarami M, McMillan A, Bero LA. Effect of telephone follow-up on the physical well-being dimension of quality of life in patients with cancer. Pharmacotherapy. 2002 Oct; 22(10):1301-11.
        View in: PubMed
      105. Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA, Bero LA. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health Syst Pharm. 2002 Aug 15; 59(16):1518-26.
        View in: PubMed
      106. Shamasunder B, Bero L. Financial ties and conflicts of interest between pharmaceutical and tobacco companies. JAMA. 2002 Aug 14; 288(6):738-44.
        View in: PubMed
      107. Rochon PA, Bero LA, Bay AM, Gold JL, Dergal JM, Binns MA, Streiner DL, Gurwitz JH. Comparison of review articles published in peer-reviewed and throwaway journals. JAMA. 2002 Jun 5; 287(21):2853-6.
        View in: PubMed
      108. Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagin A, Yank V, MacLennan G, Gøtzsche PC, Bero LA. Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA. 2002 Jun 5; 287(21):2769-71.
        View in: PubMed
      109. Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with methodological quality of clinical research articles. JAMA. 2002 Jun 5; 287(21):2805-8.
        View in: PubMed
      110. Montini T, Mangurian C, Bero LA. Assessing the evidence submitted in the development of a workplace smoking regulation: the case of Maryland. Public Health Rep. 2002 May-Jun; 117(3):291-8.
        View in: PubMed
      111. Malone RE, Wenger LD, Bero LA. High school journalists' perspectives on tobacco. J Health Commun. 2002 Mar-Apr; 7(2):139-56.
        View in: PubMed
      112. Ober M, Shohara R, Rennie D, Yank V, Bero LA. The Criticism Management System for the Cochrane Library. Eval Health Prof. 2002 Mar; 25(1):98-115.
        View in: PubMed
      113. Schotland MS, Bero LA. Evaluating public commentary and scientific evidence submitted in the development of a risk assessment. Risk Anal. 2002 Feb; 22(1):131-40.
        View in: PubMed
      114. Bero LA, Montini T, Bryan-Jones K, Mangurian C. Science in regulatory policy making: case studies in the development of workplace smoking restrictions. Tob Control. 2001 Dec; 10(4):329-36.
        View in: PubMed
      115. Bero L. Implications of the tobacco industry documents for public health and policy. Annu Rev Public Health. 2003; 24:267-88.
        View in: PubMed
      116. Wenger LD, Malone RE, George A, Bero LA. Cigar magazines: using tobacco to sell a lifestyle. Tob Control. 2001 Sep; 10(3):279-84.
        View in: PubMed
      117. Montini T, Bero LA. Policy makers' perspectives on tobacco control advocates' roles in regulation development. Tob Control. 2001 Sep; 10(3):218-24.
        View in: PubMed
      118. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, Grilli R, Harvey E, Oxman A, O'Brien MA. Changing provider behavior: an overview of systematic reviews of interventions. Med Care. 2001 Aug; 39(8 Suppl 2):II2-45.
        View in: PubMed
      119. Shojania KG, Bero LA. Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy. Eff Clin Pract. 2001 Jul-Aug; 4(4):157-62.
        View in: PubMed
      120. Bero LA. "Educational" advertisements--I haven't seen one yet! West J Med. 2001 Jun; 174(6):395.
        View in: PubMed
      121. Wenger L, Malone R, Bero L. The cigar revival and the popular press: a content analysis, 1987-1997. Am J Public Health. 2001 Feb; 91(2):288-91.
        View in: PubMed
      122. Mangurian CV, Bero LA. Lessons learned from the tobacco industry's efforts to prevent the passage of a workplace smoking regulation. Am J Public Health. 2000 Dec; 90(12):1926-30.
        View in: PubMed
      123. Anderson J, Baum M, Bero LA, Chalmers I, Chapman S, Deary IJ, Ebrahim S, Evans M, Farrell M, Greaves D, Higginson I, Hippisley-Cox J, James B, McKenzie H, Macaulay AC, Rabow M, Smyth RL, Stores G, Wolpert L. Music to be born to, music to die to. BMJ. 2000 Dec 23-30; 321(7276):1577-9.
        View in: PubMed
      124. Boyd EA, Bero LA. Assessing faculty financial relationships with industry: A case study. JAMA. 2000 Nov 1; 284(17):2209-14.
        View in: PubMed
      125. Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB. Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000 Jun 1; 342(22):1645-50.
        View in: PubMed
      126. Malone RE, Bero LA. Cigars, youth, and the Internet link. Am J Public Health. 2000 May; 90(5):790-2.
        View in: PubMed
      127. Bero LA, Mays NB, Barjesteh K, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000; (2):CD000336.
        View in: PubMed
      128. Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2000; (2):CD000172.
        View in: PubMed
      129. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000; (3):CD000336.
        View in: PubMed
      130. Bero LA. Accepting commercial sponsorship. Disclosure helps--but is not a panacea. BMJ. 1999 Sep 11; 319(7211):653-4.
        View in: PubMed
      131. Kennedy GE, Bero LA. Print media coverage of research on passive smoking. Tob Control. 1999; 8(3):254-60.
        View in: PubMed
      132. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998 Aug 15; 317(7156):465-8.
        View in: PubMed
      133. Misakian AL, Bero LA. Publication bias and research on passive smoking: comparison of published and unpublished studies. JAMA. 1998 Jul 15; 280(3):250-3.
        View in: PubMed
      134. Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach different conclusions. JAMA. 1998 May 20; 279(19):1566-70.
        View in: PubMed
      135. Bero LA. Disclosure policies for gifts from industry to academic faculty. JAMA. 1998 Apr 1; 279(13):1031-2.
        View in: PubMed
      136. Bero LA, Jadad AR. How consumers and policymakers can use systematic reviews for decision making. Ann Intern Med. 1997 Jul 1; 127(1):37-42.
        View in: PubMed
      137. Barnes DE, Bero LA. Scientific quality of original research articles on environmental tobacco smoke. Tob Control. 1997; 6(1):19-26.
        View in: PubMed
      138. Granados A, Jonsson E, Banta HD, Bero L, Bonair A, Cochet C, Freemantle N, Grilli R, Grimshaw J, Harvey E, Levi R, Marshall D, Oxman A, Pasart L, Räisänen V, Rius E, Espinas JA. EUR-ASSESS Project Subgroup Report on Dissemination and Impact. Int J Technol Assess Health Care. 1997; 13(2):220-86.
        View in: PubMed
      139. Stryer D, Bero LA. Characteristics of materials distributed by drug companies. An evaluation of appropriateness. J Gen Intern Med. 1996 Oct; 11(10):575-83.
        View in: PubMed
      140. Gill PS, Freemantle N, Bero L, Haaijer-Ruskamp F, Markela M, Barjesteh KP. GPs' prescribing behaviour may be affected by drug promotion. BMJ. 1996 Aug 10; 313(7053):367.
        View in: PubMed
      141. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996 Mar 1; 124(5):485-9.
        View in: PubMed
      142. Stryer DB, Lurie P, Bero LA. Dear doctor ... regarding calcium channel blockers. JAMA. 1996 Feb 21; 275(7):517-9.
        View in: PubMed
      143. Phillips KA, Bero LA. Improving the use of information in medical effectiveness research. Int J Qual Health Care. 1996 Feb; 8(1):21-30.
        View in: PubMed
      144. Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care. 1996; 12(2):209-37.
        View in: PubMed
      145. Barnes DE, Bero LA. Industry-funded research and conflict of interest: an analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. J Health Polit Policy Law. 1996; 21(3):515-42.
        View in: PubMed
      146. Bero L, Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA. 1995 Dec 27; 274(24):1935-8.
        View in: PubMed
      147. de Vries TP, Henning RH, Hogerzeil HV, Bapna JS, Bero L, Kafle KK, Mabadeje Af, Santoso B, Smith AJ. Impact of a short course in pharmacotherapy for undergraduate medical students: an international randomised controlled study. Lancet. 1995 Dec 2; 346(8988):1454-7.
        View in: PubMed
      148. Hornbein T, Bero L, Rennie D. The publication of commercially supported supplements statement. Anesth Analg. 1995 Oct; 81(4):887-8; author reply 888-9.
        View in: PubMed
      149. Slade J, Bero LA, Hanauer P, Barnes DE, Glantz SA. Nicotine and addiction. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):225-33.
        View in: PubMed
      150. Glantz SA, Barnes DE, Bero L, Hanauer P, Slade J. Looking through a keyhole at the tobacco industry. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):219-24.
        View in: PubMed
      151. Hanauer P, Slade J, Barnes DE, Bero L, Glantz SA. Lawyer control of internal scientific research to protect against products liability lawsuits. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):234-40.
        View in: PubMed
      152. Barnes DE, Hanauer P, Slade J, Bero LA, Glantz SA. Environmental tobacco smoke. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):248-53.
        View in: PubMed
      153. Bero L, Barnes DE, Hanauer P, Slade J, Glantz SA. Lawyer control of the tobacco industry's external research program. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):241-7.
        View in: PubMed
      154. Kearney TE, Olson KR, Bero LA, Heard SE, Blanc PD. Health care cost effects of public use of a regional poison control center. West J Med. 1995 Jun; 162(6):499-504.
        View in: PubMed
      155. Stryer DB, Bero LA. Drug promotion. N Engl J Med. 1995 Apr 13; 332(15):1032; author reply 1033.
        View in: PubMed
      156. Glantz SA, Bero LA. Inappropriate and appropriate selection of 'peers' in grant review. JAMA. 1994 Jul 13; 272(2):114-6.
        View in: PubMed
      157. Cho MK, Bero LA. Instruments for assessing the quality of drug studies published in the medical literature. JAMA. 1994 Jul 13; 272(2):101-4.
        View in: PubMed
      158. Bero LA, Glantz SA, Rennie D. Publication bias and public health policy on environmental tobacco smoke. JAMA. 1994 Jul 13; 272(2):133-6.
        View in: PubMed
      159. Bero LA, Galbraith A, Rennie D. Sponsored symposia on environmental tobacco smoke. JAMA. 1994 Feb 23; 271(8):612-7.
        View in: PubMed
      160. Lipton HL, Bird JA, Bero LA, McPhee SJ. Assessing the appropriateness of physician prescribing for geriatric outpatients. Development and testing of an instrument. J Pharm Technol. 1993 May-Jun; 9(3):107-13.
        View in: PubMed
      161. Bero LA, Galbraith A, Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med. 1992 Oct 15; 327(16):1135-40.
        View in: PubMed
      162. Lipton HL, Bero LA, Bird JA, McPhee SJ. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing. A randomized controlled trial. Med Care. 1992 Jul; 30(7):646-58.
        View in: PubMed
      163. Bero LA, Lipton HL, Bird JA. Characterization of geriatric drug-related hospital readmissions. Med Care. 1991 Oct; 29(10):989-1003.
        View in: PubMed
      164. Rennie D, Bero LA. Throw it away, Sam: the controlled circulation journals. AJR Am J Roentgenol. 1990 Oct; 155(4):889-92.
        View in: PubMed
      165. Bero LA, Roy S, Lee NM. Identification of endogenous opioid receptor components in rat brain using a monoclonal antibody. Mol Pharmacol. 1988 Nov; 34(5):614-20.
        View in: PubMed
      166. Bero LA, Lurie SN, Kuhn CM. Early ontogeny of kappa-opioid receptor regulation of prolactin secretion in the rat. Brain Res. 1987 Dec 15; 465(1-2):189-96.
        View in: PubMed
      167. Braude MC, Szeto HH, Kuhn CM, Bero L, Ignar D, Field E, Lurie S, Chasnoff IJ, Mendelson JH, Zuckerman B, et al. Perinatal effects of drugs of abuse. Fed Proc. 1987 May 15; 46(7):2446-53.
        View in: PubMed
      168. Bero LA, Kuhn CM. Role of serotonin in opiate-induced prolactin secretion and antinociception in the developing rat. J Pharmacol Exp Ther. 1987 Mar; 240(3):831-6.
        View in: PubMed
      169. Bero LA, Kuhn CM. Differential ontogeny of opioid, dopaminergic and serotonergic regulation of prolactin secretion. J Pharmacol Exp Ther. 1987 Mar; 240(3):825-30.
        View in: PubMed
      170. Kuhn C, Bero L, Ignar D, Lurie S, Field E. Endocrine consequences of perinatal methadone exposure. NIDA Res Monogr. 1987; 78:72-94.
        View in: PubMed
      171. Bero LA, Kuhn CM. Catecholaminergic regulation of opiate-stimulated growth hormone secretion in the developing rat. J Pharmacol Exp Ther. 1986 Apr; 237(1):137-42.
        View in: PubMed
      172. Kilts CD, Bero LA. Quantitative determination of 5-hydroxytryptophan in dissected brain regions by on-line trace enrichment HPLC with electrochemical detection. Life Sci. 1984 Jul 2; 35(1):87-95.
        View in: PubMed
      Back to TOP